These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38619788)

  • 1. Comparative Study on Anti-VEGF in Wet Age-Related Macular Degeneration in the Setting Based on Lean Methodology from the Bari Intravitreal Injection Registry (BIVIR).
    Grassi MO; Viggiano P; Borrelli E; Boscia G; Molfetta T; Malerba MG; D'Addario M; Giancipoli E; Alessio G; Boscia F
    Ophthalmol Ther; 2024 Jun; 13(6):1619-1634. PubMed ID: 38619788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
    Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
    Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Lukacs R; Schneider M; Nagy ZZ; Sandor GL; Kaan K; Asztalos A; Enyedi L; Pek G; Barcsay G; Szabo A; Borbandy A; Kovacs I; Resch MD; Papp A
    BMC Ophthalmol; 2023 Mar; 23(1):110. PubMed ID: 36932356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
    Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
    Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
    Luu KT; Seal J; Green M; Winskill C; Attar M
    J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.